The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)

Abstract Background The incidence of bilateral breast cancer (BBC) is increasing nowadays comprising 2%‐11% of all breast cancer (BC). According to the interval time between the first and second cancer, BBC could be divided into synchronous (SBBC) and metachronous (MBBC). However, this interval time...

Full description

Bibliographic Details
Main Authors: Bo Pan, Ying Xu, Yi‐Dong Zhou, Ru Yao, Huan‐Wen Wu, Qing‐Li Zhu, Chang‐Jun Wang, Feng Mao, Yan Lin, Song‐Jie Shen, Qiang Sun
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.2198
id doaj-26cb65cf0692478b8ead2fe3fc081e91
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Bo Pan
Ying Xu
Yi‐Dong Zhou
Ru Yao
Huan‐Wen Wu
Qing‐Li Zhu
Chang‐Jun Wang
Feng Mao
Yan Lin
Song‐Jie Shen
Qiang Sun
spellingShingle Bo Pan
Ying Xu
Yi‐Dong Zhou
Ru Yao
Huan‐Wen Wu
Qing‐Li Zhu
Chang‐Jun Wang
Feng Mao
Yan Lin
Song‐Jie Shen
Qiang Sun
The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
Cancer Medicine
bilateral breast cancer
metachronous
survival
synchronous
unilateral
author_facet Bo Pan
Ying Xu
Yi‐Dong Zhou
Ru Yao
Huan‐Wen Wu
Qing‐Li Zhu
Chang‐Jun Wang
Feng Mao
Yan Lin
Song‐Jie Shen
Qiang Sun
author_sort Bo Pan
title The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
title_short The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
title_full The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
title_fullStr The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
title_full_unstemmed The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)
title_sort prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: a meta‐analysis of studies from recent decade (2008‐2018)
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2019-06-01
description Abstract Background The incidence of bilateral breast cancer (BBC) is increasing nowadays comprising 2%‐11% of all breast cancer (BC). According to the interval time between the first and second cancer, BBC could be divided into synchronous (SBBC) and metachronous (MBBC). However, this interval time is quite different across studies. It remains controversial whether the survival of BBC, SBBC, and MBBC is similar or worse compared to that of unilateral breast cancer (UBC), and whether the survival of SBBC is similar or worse compared to MBBC. To better understand the survival of UBC, BBC, SBBC, and MBBC and how the interval time would influence the prognosis of SBBC and MBBC, we performed this meta‐analysis on studies from recent 10 years (2008‐2018). Methods Databases of PubMed, Embase, and Web of Science were searched for relevant studies within recent 10 years. Hazard ratio (HR) was adopted to evaluate the difference of overall survival (OS) of UBC, BBC, SBBC, and MBBC. HR of OS comparisons were performed between BBC vs UBC, SBBC vs UBC, MBBC vs UBC, and SBBC vs MBBC with 3, 6, 12 months as the interval time, respectively. Results There were 15 studies of 72 302 UBC and 2912 BBC included in the meta‐analysis. The summary HR of OS comparison between BBC vs UBC was 1.68 (95% CI: 1.28‐2.20), SBBC vs UBC was 2.01 (95% CI: 1.14‐3.55), MBBC vs UBC was 3.22 (95% CI: 0.75‐13.78). When 3, 6, 12 months were used as the interval time, the summary HR of the OS comparison between of SBBC vs MBBC were 0.64 (95% CI: 0.44‐0.94), 1.17 (95% CI: 0.84‐1.63) and 1.45 (95% CI: 1.10‐1.92), respectively. Conclusion BBC and SBBC showed worse prognosis in terms of OS compared to UBC while MBBC manifested similar or non‐superior survival as UBC. The OS comparison between SBBC and MBBC changed with different interval time used. The longer the interval time used, the worse the survival of SBBC. SBBC with interval of 3‐12 months between the two cancers had the worst prognosis. When 6 months was used to differentiate SBBC from MBBC, these two clinical entities showed similar OS.
topic bilateral breast cancer
metachronous
survival
synchronous
unilateral
url https://doi.org/10.1002/cam4.2198
work_keys_str_mv AT bopan theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yingxu theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yidongzhou theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT ruyao theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT huanwenwu theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT qinglizhu theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT changjunwang theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT fengmao theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yanlin theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT songjieshen theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT qiangsun theprognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT bopan prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yingxu prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yidongzhou prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT ruyao prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT huanwenwu prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT qinglizhu prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT changjunwang prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT fengmao prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT yanlin prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT songjieshen prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
AT qiangsun prognosticcomparisonamongunilateralbilateralsynchronousbilateralandmetachronousbilateralbreastcancerametaanalysisofstudiesfromrecentdecade20082018
_version_ 1724781740076040192
spelling doaj-26cb65cf0692478b8ead2fe3fc081e912020-11-25T02:40:25ZengWileyCancer Medicine2045-76342019-06-01862908291810.1002/cam4.2198The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta‐analysis of studies from recent decade (2008‐2018)Bo Pan0Ying Xu1Yi‐Dong Zhou2Ru Yao3Huan‐Wen Wu4Qing‐Li Zhu5Chang‐Jun Wang6Feng Mao7Yan Lin8Song‐Jie Shen9Qiang Sun10Department of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Pathology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Ultrasound Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaDepartment of Breast Surgery Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing P. R. ChinaAbstract Background The incidence of bilateral breast cancer (BBC) is increasing nowadays comprising 2%‐11% of all breast cancer (BC). According to the interval time between the first and second cancer, BBC could be divided into synchronous (SBBC) and metachronous (MBBC). However, this interval time is quite different across studies. It remains controversial whether the survival of BBC, SBBC, and MBBC is similar or worse compared to that of unilateral breast cancer (UBC), and whether the survival of SBBC is similar or worse compared to MBBC. To better understand the survival of UBC, BBC, SBBC, and MBBC and how the interval time would influence the prognosis of SBBC and MBBC, we performed this meta‐analysis on studies from recent 10 years (2008‐2018). Methods Databases of PubMed, Embase, and Web of Science were searched for relevant studies within recent 10 years. Hazard ratio (HR) was adopted to evaluate the difference of overall survival (OS) of UBC, BBC, SBBC, and MBBC. HR of OS comparisons were performed between BBC vs UBC, SBBC vs UBC, MBBC vs UBC, and SBBC vs MBBC with 3, 6, 12 months as the interval time, respectively. Results There were 15 studies of 72 302 UBC and 2912 BBC included in the meta‐analysis. The summary HR of OS comparison between BBC vs UBC was 1.68 (95% CI: 1.28‐2.20), SBBC vs UBC was 2.01 (95% CI: 1.14‐3.55), MBBC vs UBC was 3.22 (95% CI: 0.75‐13.78). When 3, 6, 12 months were used as the interval time, the summary HR of the OS comparison between of SBBC vs MBBC were 0.64 (95% CI: 0.44‐0.94), 1.17 (95% CI: 0.84‐1.63) and 1.45 (95% CI: 1.10‐1.92), respectively. Conclusion BBC and SBBC showed worse prognosis in terms of OS compared to UBC while MBBC manifested similar or non‐superior survival as UBC. The OS comparison between SBBC and MBBC changed with different interval time used. The longer the interval time used, the worse the survival of SBBC. SBBC with interval of 3‐12 months between the two cancers had the worst prognosis. When 6 months was used to differentiate SBBC from MBBC, these two clinical entities showed similar OS.https://doi.org/10.1002/cam4.2198bilateral breast cancermetachronoussurvivalsynchronousunilateral